Basophil activation test for allergic and febrile non-haemolytic transfusion reactions among paediatric patients with haematological or oncological disease.
IgE
allergen
allergic transfusion reactions
anaphylaxis
febrile non-haemolytic transfusion reactions
hypersensitivity
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
09
09
2022
received:
21
06
2022
accepted:
18
09
2022
pubmed:
13
10
2022
medline:
17
1
2023
entrez:
12
10
2022
Statut:
ppublish
Résumé
Allergic transfusion reactions (ATRs) and febrile non-haemolytic transfusion reactions (FNHTRs) are common, although their mechanisms remain unclear. Immunoglobulin E (IgE)-mediated type I hypersensitivity may be involved in the pathogenesis of ATR. A basophil activation test (BAT) may help elucidate this process. The BAT was based on peripheral blood samples from paediatric patients with a haematological or oncological disease and on samples of residual blood products transfused in each case. Dasatinib was used to evaluate whether basophil activation was mediated by an IgE-dependent pathway. Twenty-seven patients with and 19 patients without ATR/FNHTR were included in this study, respectively. The median BAT values associated with ATR- (n = 41) and FNHTR-causing (n = 5) blood products were 22.1% (range = 6.1%-77.0%) and 27.8% (range = 15.2%-47.8%), respectively, which were higher than the median value of 8.5% (range = 1.1%-40.9%) observed in blood products without a transfusion reaction. Dasatinib suppressed basophil activity. BAT values were comparable in patients with ATR regardless of severity. Meanwhile, BAT values analysed with blood products non-causal for ATR/FNHTR were higher in patients with ATR/FNHTR than in those without. The IgE-mediated type I hypersensitivity may be involved in the pathogenesis of ATR and FNHTR. BAT analyses may help elucidate the underlying mechanisms and identify patients at risk.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Allergic transfusion reactions (ATRs) and febrile non-haemolytic transfusion reactions (FNHTRs) are common, although their mechanisms remain unclear. Immunoglobulin E (IgE)-mediated type I hypersensitivity may be involved in the pathogenesis of ATR. A basophil activation test (BAT) may help elucidate this process.
MATERIALS AND METHODS
METHODS
The BAT was based on peripheral blood samples from paediatric patients with a haematological or oncological disease and on samples of residual blood products transfused in each case. Dasatinib was used to evaluate whether basophil activation was mediated by an IgE-dependent pathway.
RESULTS
RESULTS
Twenty-seven patients with and 19 patients without ATR/FNHTR were included in this study, respectively. The median BAT values associated with ATR- (n = 41) and FNHTR-causing (n = 5) blood products were 22.1% (range = 6.1%-77.0%) and 27.8% (range = 15.2%-47.8%), respectively, which were higher than the median value of 8.5% (range = 1.1%-40.9%) observed in blood products without a transfusion reaction. Dasatinib suppressed basophil activity. BAT values were comparable in patients with ATR regardless of severity. Meanwhile, BAT values analysed with blood products non-causal for ATR/FNHTR were higher in patients with ATR/FNHTR than in those without.
CONCLUSION
CONCLUSIONS
The IgE-mediated type I hypersensitivity may be involved in the pathogenesis of ATR and FNHTR. BAT analyses may help elucidate the underlying mechanisms and identify patients at risk.
Substances chimiques
Dasatinib
RBZ1571X5H
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
41-48Informations de copyright
© 2022 International Society of Blood Transfusion.
Références
Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. Blood. 2019;133:1831-9.
Yanagisawa R. Preventing adverse reactions in pediatric transfusions using washed platelet concentrate. Pediatr Int. 2021;63:391-403.
Savage WJ. Transfusion reactions. Hematol Oncol Clin North Am. 2016;30:619-34.
Savage WJ, Tobian AA, Savage JH, Hamilton RG, Ness PM. Atopic predisposition of recipients in allergic transfusion reactions to apheresis platelets. Transfusion. 2011;51:2337-42.
Yanagisawa R, Ishimine N, Komori K, Kurata T, Saito S, Tanaka M, et al. Relationship between allergic transfusion reactions and allergic predisposition among pediatric patients with hematological/oncological disease. Transfusion. 2022;62:1035-44.
Okamura I, Matsuyama N, Yasui K, Hirayama F, Ikeda T. Clinical utility of the basophil activation test for analysis of allergic transfusion reactions: a pilot study. Vox Sang. 2017;112:114-21.
Matsuyama N, Yasui K, Amakishi E, Hayashi T, Kuroishi A, Ishii H, et al. The IgE-dependent pathway in allergic transfusion reactions: involvement of donor blood allergens other than plasma proteins. Int J Hematol. 2015;102:93-100.
Choi Y, Byun JM, Kim I, Park JH, Kim KH, Kim JS, et al. Successful management of severe allergic reactions to platelet transfusion with omalizumab: a case report. Medicine (Baltimore). 2021;100:e27724.
Shi S, Han J, Yao Y, Xu Y, Wu D, Wang Y. Successful prevention of severe allergic transfusion reactions with omalizumab. Transfusion. 2020;60:1639-42.
Yasui K, Takihara Y, Matsuyama N, Kato H, Oka K, Imada K, et al. Sensitivity and specificity of passive immune-basophil activation test to detect allergic transfusion reactions. Transfusion. 2019;59:3308-13.
Yanagisawa R, Tatsuzawa Y, Ono T, Kobayashi J, Tokutake Y, Hidaka E, et al. Analysis of clinical presentations of allergic transfusion reactions and febrile non-haemolytic transfusion reactions in paediatric patients. Vox Sang. 2019;114:826-34.
Ide Y, Yanagisawa R, Kobayashi J, Komori K, Matsuda K, Amano Y, et al. Relationship between allergic sensitisation-associated single-nucleotide polymorphisms and allergic transfusion reactions and febrile non-haemolytic transfusion reactions in paediatric cases. Blood Transfus. 2022;20:94-102.
Yanagisawa R, Shimodaira S, Sakashita K, Hidaka Y, Kojima S, Nishijima F, et al. Factors related to allergic transfusion reactions and febrile non-haemolytic transfusion reactions in children. Vox Sang. 2016;110:376-84.
Yasui K, Enami T, Okamura-Shiki I, Ueda T, Fukushima K, Matsuyama N, et al. Passive immune basophil activation test for the identification of allergic episodes from various adverse events elicited by haematopoietic cell transplantation: a pilot study. Vox Sang. 2022;117:119-27.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452-8.
Nagao M, Hiraguchi Y, Hosoki K, Tokuda R, Usui T, Masuda S, et al. Allergen-induced basophil CD203c expression as a biomarker for rush immunotherapy in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol. 2008;146:47-53.
Hemmings O, Kwok M, McKendry R, Santos AF. Basophil activation test: old and new applications in allergy. Curr Allergy Asthma Rep. 2018;18:77.
Santos AF, Alpan O, Hoffmann HJ. Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice. Allergy. 2021;76:2420-32.
Yanagisawa R, Yamanaka R, Shimodaira S. Analysis of clinical factors associated with the occurrence time of allergic transfusion reactions or febrile non-hemolytic transfusion reactions. Ann Clin Lab Sci. 2022;52:382-90.
Li J, Best OG, Rose MA, Green SL, Fulton RB, Fernando SL. Integrating basophil activation tests into evaluation of perioperative anaphylaxis to neuromuscular blocking agents. Br J Anaesth. 2019;123:e135-43.
Curto-Barredo L, Yelamos J, Gimeno R, Mojal S, Pujol RM, Giménez-Arnau A. Basophil activation test identifies the patients with chronic spontaneous urticaria suffering the most active disease. Immun Inflamm Dis. 2016;4:441-5.